Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial
<p><strong>Background: </strong>Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish...
Main Authors: | Mo, Y, Booraphun, S, Li, AY, Domthong, P, Kayastha, G, Lau, YH, Chetchotisakd, P, Limmathurotsakul, D, Tambyah, PA, Cooper, BS |
---|---|
Other Authors: | REGARD-VAP investigators |
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2024
|
Similar Items
-
Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial
by: Mo, Y, et al.
Published: (2021) -
Making individualised risk assessment ‘business as usual’ in preoperative assessment
by: A. Gadelkareem, et al.
Published: (2023-06-01) -
Trimethoprim-sulfamethoxazole versus trimethoprimsulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): A multicentre, double-blind, non-inferiority, randomised controlled trial
by: Chetchotisakd, P, et al.
Published: (2014) -
Trimethoprim-sulfamethoxazole versus trimethoprimsulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): A multicentre, double-blind, non-inferiority, randomised controlled trial
by: Chetchotisakd, P, et al.
Published: (2014) -
Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.
by: Chetchotisakd, P, et al.
Published: (2014)